- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 23.1 Consent of Ernst & Young LLP Independent Public Accountants
- 31.1 Certification of the CEO Pursuant to Section 302 of the Sarbanes-oxley Act
- 31.2 Certification of the CFO Pursuant to Section 302 of the Sarbanes-oxley Act
- 32.1 Certification of the CEO Pursuant to Section 906 of the Sarbanes-oxley Act
- 32.2 Certification of the CFO Pursuant to Section 906 of the Sarbanes-oxley Act
- 99.1 Risk Factors
Exhibit 32.1
GENOME THERAPEUTICS CORP. AND SUBSIDIARY
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Genome Therapeutics Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2003 as filed with the Securities and Exchange Commission (the “Report”), I, Steven M. Rauscher, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ STEVEN M. RAUSCHER Steven M. Rauscher President & Chief Executive Officer |
Date: March 5, 2004